- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03856268
Understanding the Roles of Hormones in Adipocyte Remodeling Following Menopause (RESUME-2)
Understanding the Roles of Estradiol and Follicle-stimulating Hormone in Adipocyte Remodeling Following Surgical and Pharmacology-induced Menopause (RESUME-2 Study)
The overarching aims of this study are to:
- Characterize the rate of in vivo adipogenesis, and changes in adipose tissue gene and protein expression, in the scABD and scFEM depots of women undergoing surgical menopause (↓E2, ↑FSH).
- Characterize the rate of in vivo adipogenesis, and changes in adipose tissue gene and protein expression, in the scABD and scFEM depots of women undergoing gonadal suppression (↓E2, ↓FSH).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a cross-sectional study where two groups of premenopausal women (ages 18-50 y) will be enrolled in a parallel arm study:
- Arm 1 (Surgical Menopause): up to 6 women undergoing laparoscopic, elective bilateral oophorectomy [Site: Pennington Biomedical Research Center].
- Arm 2 (Pharmacology-Induced Menopause): up to 6 women undergoing gonadal suppression via leuprolide acetate (Lupron [AbbVie Inc.]) [Site: UC-Denver].
We will compare each arm of women to non-oophorectomized, premenopausal women (controls) with normal menstrual cycles (Apple&Pear study; NCT01748994; PI: Ravussin) selectively matched (1:2) for age and BMI. The Apple&Pear study uses the same in vivo adipogenesis labeling protocol, with similar age and BMI criteria, as the proposed study.
Study Type
Contacts and Locations
Study Locations
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808
- Pennington Biomedical Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
INCLUSION CRITERIA:
- Healthy female
- Ages 18-50 y
- Planning to have either a laparoscopic bilateral oophorectomy or a laparoscopic unilateral oophorectomy (which would result in no remaining ovaries)
- Are willing to drink heavy water (2H2O) over an 8-week period
- Medically cleared for participation in the study by OB/GYN and Medical Investigator
- Are willing to have blood and fat tissue stored for future use
EXCLUSION CRITERIA:
- Meet either of the following criteria:
- Have all 3 of the major menopause-related symptoms [hot flashes, mood swings, insomnia (trouble sleeping)]
- Have 2 of the major menopause-related symptom combinations [hot flashes and mood swings, or hot flashes and insomnia (trouble sleeping)]
- Unstable weight in the last 3 months [gain or loss >7 lb (or 3.2 kg)]
- History of clinically diagnosed diabetes or a fasting blood glucose >126 mg/dL
- Chronic use of systemic glucocorticoids, antipsychotic/antidepressant medications, thiazolidinediones and other medications that cause clinically significant weight gain, weight loss or are known to make changes in fat cell number/size *
- Previous bariatric surgery (or other surgeries) for obesity or weight loss (< 3 years ago)
- Use of over the counter or prescription weight loss products
- History of metabolic diseases (other than diabetes)
- History of neurological disease
- History of cardiovascular disease (or other chronic diseases)
- Pregnant, planning to become pregnant, or breastfeeding
- Use of hormone replacement therapy
Unwilling to discontinue any form or hormonal therapy (e.g., contraceptives including birth control pills, vaginal ring, injections, implant, or skin patch; hormonal supplements, etc.) upon enrollment (after the Screening Visit).
- Inconsistent use of medications listed above will be evaluated and left up to the discretion of the Medical Investigator to evaluate safety.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
ARM 1: 'Surgical Menopause' Group
Premenopausal women having an oophorectomy.
|
Women undergoing laparoscopic oophorectomy surgery ('surgical menopause') will be enrolled at Pennington Biomedical.
Other Names:
|
ARM 2: "Drug-Induced Menopause'
Premenopausal women with gonadal suppression
|
Women undergoing gonadal suppression via leuprolide acetate (Lupron [AbbVie Inc.]) will be enrolled at the University of Colorado-Denver.
Other Names:
|
'Comparative (Control)' Group
Premenopausal women with regular cycles.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of in vivo adipogenesis (via deuterium-enrichment of adipose tissue DNA)
Time Frame: Change from baseline in enrichment of DNA of adipose cells with deuterium at 8 weeks
|
Deuterium from the deuterium-labeled water is incorporated into the newly-synthesized DNA of newly-formed fat cell precursor cells through cell replication.
The latter carry over the label when they become fat cells through differentiation.
Enzymatic digestion of the fat tissue isolates the individual cells constituting the fat tissue.
Centrifugation of the cell suspension allows the separation of fat cells into a floating layer and a pellet comprised of stromal-vascular cells including the fat cell precursor cells and small fat cells.
As the fat cell precursor cells and small adipocytes have the property to attach quickly to plastic surfaces of culture dishes, a brief culturing of the stromal-vascular cells sorts these cells from the remaining cells.
Thus, measuring the deuterium-enrichment of DNA from plastic-adherent stromal-vascular cells indicates the rate of in vivo formation of new mature fat cells and pre-adipocytes, a process collectively termed adipogenesis.
|
Change from baseline in enrichment of DNA of adipose cells with deuterium at 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Size of adipocytes
Time Frame: Change from baseline in size of adipocytes at 8 weeks post-surgery
|
Fat cell size will be determined using osmium fixation of the lipids and measurement of their diameter with Coulter Counter followed by calculation of fat cell volume.
The mean lipid content of fat cells will be calculated by multiplying the fat cell volume by the density of triolein (0.915).
|
Change from baseline in size of adipocytes at 8 weeks post-surgery
|
Number of adipocytes
Time Frame: Change from baseline in number of adipocytes at 8 weeks post-surgery
|
Fat cell number will be estimated by dividing the volume of adipose tissue depot of interest to the mean fat cell volume or the fat mass of the depot to the mean lipid content in fat cell.
|
Change from baseline in number of adipocytes at 8 weeks post-surgery
|
Body composition (by Dual-energy X-ray Absorptiometry (DXA))
Time Frame: Change from baseline in body composition at 8 weeks post-surgery
|
Fat mass, fat-free mass, and percent body fat will be assessed using a whole-body scanner GE iDXA.
|
Change from baseline in body composition at 8 weeks post-surgery
|
Adipose tissue gene and protein expression
Time Frame: Changes from baseline in gene and protein expression at 8 weeks post-surgery
|
Expression levels of genes and proteins involved in adipocyte expansion and function (ERα, PPARγ2, C/EBPα, aromatase, adiponectin, and LPL), extracellular matrix remodeling and fibrosis (COL6(a1, a2, a3), COL4a1, and TGFβ), and inflammation (IL-6 and TNFα) will be assessed.
|
Changes from baseline in gene and protein expression at 8 weeks post-surgery
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PBRC 2019-010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adiposity
-
Johns Hopkins UniversityCompleted
-
University Hospital, BrestCompleted
-
Neothetics, IncCompletedSubcutaneous Abdominal AdiposityUnited States
-
University of SharjahAl Jalila FoundationCompleted
-
University Hospital, Basel, SwitzerlandRigshospitalet, DenmarkCompletedAdipositySwitzerland
-
University of Colorado, DenverNational Institute on Aging (NIA)Not yet recruitingMenopause | Aging | Adiposity | Estrogen DeficiencyUnited States
-
Pennington Biomedical Research CenterLouisiana Clinical and Translational Science CenterTerminatedAdiposity | Menopause Surgical | Estrogen DeficiencyUnited States
-
University of Southern CaliforniaTerminatedAdiposity | Obesity, AbdominalUnited States
-
Erbe Elektromedizin GmbHErbe USA IncorporatedRecruitingObesity | AdiposityUnited States
-
Fudan UniversityInner Mongolia Yili Industrial Group Co., LtdCompletedObesity | AdiposityChina
Clinical Trials on 'Surgical Menopause' Group
-
Kuopio University HospitalCompletedSurgical Procedures, Operative | Acromioclavicular Joint | DislocationFinland
-
Bozok UniversityCompletedCovid-19 | Pregnant | Mask | FetusTurkey
-
Gaziantep Islam Science and Technology UniversityNot yet recruitingMenopause | Aging | Failure of Genital Response
-
Miami VA Healthcare SystemPfizerCompleted
-
Herba Buena, IncCompleted
-
Universidad Complutense de MadridYolanda García Álvarez; Francisco Javier Álvaro Afonso; David Sevillano Fernández and other collaboratorsCompleted
-
Universidad Rey Juan CarlosHospital Universitario Fundación AlcorcónCompleted
-
Semaine HealthCitruslabsCompletedMenopause | Menopause Related Conditions | Perimenopausal DisorderUnited States
-
Universidad Rey Juan CarlosHospital Universitario Fundación AlcorcónCompleted
-
Universidad Rey Juan CarlosHospital San Carlos, Madrid; Hospital Universitario Fundación AlcorcónCompletedCarpal Tunnel SyndromeSpain